The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients

Cardiotoxicity induced by tyrosine kinase inhibitors

(2009) George S. Orphanos et al.   ACTA ONCOLOGICA

Cardiovascular Effects of Tyrosine Kinase Inhibitors Used for Gastrointestinal Stromal Tumors

(2009) Vishnu Chintalgattu et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocardial Strain Measurement With 2-Dimensional Speckle-Tracking Echocardiography

(2009) Thomas H. Marwick et al.   JACC-Cardiovascular Imaging

Brain natriuretic peptide level as marker of cardiac function in imatinib—Treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy

(2008) Mario Tiribelli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Resistant Hypertension: Diagnosis, Evaluation, and Treatment

(2008) David A. Calhoun et al.   CIRCULATION

Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib

(2008) Ana Garcia-Alvarez et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

An evaluation of the cardiotoxicity of imatinib mesylate

(2008) Antonio Luiz Ribeiro et al.   LEUKEMIA RESEARCH

Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity

(2007) P. J. Perik et al.   ANNALS OF ONCOLOGY

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience

(2007) Massimo Breccia et al.   LEUKEMIA RESEARCH